Google under Alphabet Inc. (GOOGL.US) has placed an order with Intel Corporation (INTC.US) to produce more than 3 million tensor processing units (TPUs) in 2028, according to online media outlet The Information, citing people with direct knowledge of the matter.

Intel Corporation surged 11.2% overnight (8th), closing at USD110.27.

NVIDIA Corporation (NVDA.US) is reportedly evaluating whether Intel’s technology can be used to manufacture a processor that integrates four graphics chips into a single unit, but it has not yet placed an order.

Spiking demand for chips amid the AI boom has made it difficult for Taiwan Semiconductor Manufacturing Company Ltd. (TSM.US) to provide sufficient supply, report noted. This capacity crunch has prompted several major AI chip design companies to turn to Intel.
~

AASTOCKS Financial News
Website: www.aastocks.com

SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. ("Vcare PharmaTech"), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.

This collaboration strengthens the Company's cardiovascular portfolio and highlights Everest's continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.

Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.

The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market.

"This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region," said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest's cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies, Everest will drive Sumecigrel's development and commercialization to realize its full clinical and commercial value and bring new treatment options to more patients."

"As our self-developed novel antithrombotic drug, Sumecigrel represents our first innovative pharmaceutical product, "said Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech. "This strategic partnership with Everest Medicines serves as the first step of Sumecigrel's global commercialization strategy, creating a win-win situation for an original innovation enterprise and an international commercial platform. Powered by AI-driven differentiated original design, Vcare PharmaTech consistently focuses on the development of innovative drugs and leading therapies, standing as a pioneer of the next-generation original innovation in the global antiplatelet field. We will accelerate the global R&D and registration progress of Sumecigrel, consolidate its global competitive edges, and contribute Chinese innovation to the diagnosis and treatment of cardiovascular diseases across the Asia-Pacific and the world at large."

Cardio-cerebrovascular diseases rank among the leading causes of death worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global deaths. Around 85% of these deaths were attributed to myocardial infarction (a major type of ACS) and stroke. The death toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023.

Antiplatelet drugs inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area.

As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD.

About Sumecigrel

Sumecigrel is the world's first new-generation P2Y12 receptor antagonist designed to resolve clopidogrel's heavy reliance on CYP2C19 genetic polymorphism by optimizing its metabolic pathway while retaining clopidogrel's active metabolite. It is indicated for atherothrombotic events including acute coronary syndrome, ischemic stroke and peripheral arterial disease. It stands as one of Vcare PharmaTech's flagship achievements underpinned by the philosophy of differentiated original design to tackle unmet clinical needs.

Its molecular design findings were published in Journal of Medicinal Chemistry (JMC), a top journal of the American Chemical Society, and highlighted by SciBX under Nature Portfolio, which recognized it as one of the most commercially promising projects in the field of novel drugs. Currently in preparation for NDA submissions in multiple countries, Sumecigrel possesses strong Best-in-Class potential and broad commercial prospects, and is expected to reshape the antithrombotic market where no new innovative drugs targeting the same mechanism have been launched for over a decade.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

About Vcare PharmaTech

Founded in 2010 by professors from China Pharmaceutical University and overseas returnee talents, Vcare PharmaTech is a commercial-stage innovative biopharmaceutical enterprise adopting AI-enabled differentiated original drug design and dedicated to developing innovative drugs and leading therapies. The Company has built a full-spectrum innovation system covering the entire R&D and industrialization lifecycle of new drugs, from AI-powered differentiated project initiation and preclinical candidate discovery to integrated pharmaceutical development and green manufacturing.

It houses the Nanjing Key Laboratory for AI-Driven Drug Design and Nanjing Engineering Research Center for Synthetic Biology and Flow Chemistry.

Focused on addressing unmet clinical demands via differentiated approaches, Vcare PharmaTech develops a tiered, high-quality and diversified pipeline of innovative drugs targeting treatment resistance, drug resistance and targeted selectivity optimization. Its product portfolio covers major chronic disease areas including inflammation and autoimmunity, cardio-cerebrovascular diseases and oncology, striving to deliver superior treatment solutions for patients worldwide. For more information, please visit www.vcarepharmatech.com.

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Chip technology company Marvell Technology, Inc. (MRVL.US) last leaped 7% in pre-market trading on Monday (8th), last reported at USD281.88.

Index operator S&P Dow Jones Indices announced that Marvell Technology, Inc. and electronics manufacturer Flex Ltd. (FLEX.US) will be added to the S&P 500 Index, with the changes taking effect at the open of US trading on Monday, June 22.

Flex Ltd. gained 3.3% in pre-market trading, last at USD156.98. The Campbell's Company (CPB.US) and Pool Corporation (POOL.US) will be removed from the index at the same time.
~

AASTOCKS Financial News
Website: www.aastocks.com

SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented multiple clinical and preclinical results of its innovative metabolic and obesity pipeline at the 2026 American Diabetes Association's^® (ADA) Scientific Sessions. This includes three clinical oral presentations of mazdutide (GCG/GLP-1 dual agonist) across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, as well as preclinical data from its IBI3032 and IBI3042, as next‑generation oral daily and weekly GLP‑1 receptor agonists, along with IBI3040 (a novel amylin analog) and IBI3046 (an INHBE-targeting siRNA). Innovent Biologics' differentiated pipeline aims to provide scientific and comprehensive treatment options for weight management and metabolic comorbidities through offering superior tolerability, reduced muscle loss, convenient dosing, durable efficacy, and integrated comorbidity management.

Below is a summary of its early-stage pipeline results:

IBI3032 (daily oral small-molecule GLP-1) Preclinical and Phase 1 Clinical Study Results

Preclinical results:

ADA Reference: IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing Through Phase 1 Clinical Trials (Abstract No.: 1678-P)

IBI3032 is a novel, orally bioavailable non-peptidic GLP-1R agonist discovered via structure-based design, and has now advanced into Phase 1 clinical trials in both China and the United States.

IBI3032 exhibited potent activation of the human GLP-1R (EC₅₀ = 0.53 nM) with high selectivity and minimal β-arrestin recruitment. IBI3032 demonstrated favorable cross‑species pharmacokinetics and a robust preclinical efficacy profile. Pharmacokinetic studies revealed high oral exposure in cynomolgus monkeys, with a bioavailability of 24.5% and a half-life of 6.3 hours.

Importantly, compared to the marketed small‑molecule GLP‑1R agonist Orforglipron, IBI3032 demonstrates significantly superior weight‑loss efficiency—achieving markedly greater body weight loss at half of the dose in preclinical models. In a 28-day study in hGLP-1R knock-in DIO mice, oral IBI3032 produced dose-dependent body weight loss relative to vehicle (1 mg/kg: -1.8%; 6 mg/kg: -8.0%; 12 mg/kg: -10.8%). In a 28-day cynomolgus monkey study, once-daily oral administration of IBI3032 (1 mg/kg) produced 11.2% body weight loss versus vehicle.

This differentiated profile supports its potential as a best‑in‑class oral therapy. Collectively, these findings underscore IBI3032 as a next‑generation oral GLP‑1R agonist that combines true oral convenience, low‑dose efficacy, and accelerated global clinical development.

Phase 1 clinical results:

ADA Reference: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults (Abstract No.: 1690-P)

Preclinical studies indicate IBI3032 has a higher oral exposure than other marketed oral small‑molecule GLP‑1 in cynomolgus monkeys and shows encouraging efficacy signals for weight loss in obese cynomolgus monkeys. Based on these preclinical findings, two Phase 1 studies were designed to preliminarily assess the human dose range, weight-loss efficacy signals, and safety and tolerability of IBI3032, further validate the hypothesis of potent weight loss at low doses, and provide key data to inform the subsequent clinical trial design.

Study Design: The single-ascending dose (SAD) study recruited 40 eligible participants with/without overweight or obesity (BMI 20–40 kg/m²) to receive once-daily single doses of IBI3032 at 0.3 mg, 1.0 mg, 3.0 mg and 6.0 mg. The multiple-ascending dose (MAD) study recruited a total of 79 overweight/obese participants (BMI 24–40 kg/m²) to receive once-daily oral IBI3032 for 4 weeks per protocol-specified dose titration ranging from 0.6 mg to 10 mg, aiming to evaluate multiple dose-escalation titration regimens.

Clinical Study Findings:

• Linear pharmacokinetics properties support once-daily oral administration: After a single oral dose, IBI3032's systemic exposure (AUC_inf and C_max) increased in an approximately dose-proportional manner across 0.3–6 mg dose range; peak plasma concentration (T_max) occurred 5–12 hours post-dose. Its terminal elimination half-life is (T_1/2) approximately 2 days, which supports a once-daily dosing regimen. Pharmacokinetics (PK) parameters after 4 weeks of sequential titration in MAD were consistent with SAD and exhibited linear PK characteristics.
• Overall manageable safety profile: IBI3032 showed a manageable safety profile in both SAD and MAD studies; nearly all treatment-emergent adverse events were mild to moderate, with no treatment-related serious adverse events reported. No cases of acute pancreatitis, acute kidney injury, acute gallbladder disease, major adverse cardiovascular events, thyroid C-cell hyperplasia or thyroid carcinoma were reported in either study.
• Gradual dose titration balances weight-loss efficacy and treatment tolerability: Four-week cohort comparisons within MAD study demonstrated that low starting dose with stepwise dose escalation enables substantial weight reduction alongside meaningful improvement in gastrointestinal tolerability. In the cohort starting at 0.6 mg with seven-step escalation to 9 mg (n=12), 4-week treatment led to an average 10.11% body weight reduction after 4 weeks, while vomiting incidence remained at 8.3%. Compared with other cohorts utilizing the aggressive escalation approach with high starting doses and large dose increments, this slow titration regimen with lower initial dose, smaller incremental jumps and prolonged escalation cycle lowers gastrointestinal adverse event risk while retaining weight-lowering efficacy, providing evidence for future clinical dosing regimen development.

Ongoing Development in Phase 1: Additional Phase 1 clinical study of IBI3032 is ongoing to further explore and refine optimal dose titration schemes. Leveraging its differentiated attributes of superior oral exposure and low effective therapeutic dose, the program aims to validate the molecule's potential of potent weight loss under acceptable safety and tolerability.

IBI3040 (novel Amylin) Preclinical Results

ADA Reference: IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical Models (Abstract No.: 3077-LB)

IBI3040 is a highly potent agonist of the amylin and calcitonin (CTR) receptors. In a 2-week study in DIO rats, IBI3040 at 2 and 10 nmol/kg Q3D resulted in dose-dependent reductions in body weight of 8.82% and 11.11%, respectively, compared to vehicle-treated rats. In another study, the combination of IBI3040 and semaglutide resulted in a greater weight reduction of −14.7%, whereas monotherapy with IBI3040 or semaglutide produced weight losses of −10.12% and −3.01% in DIO rats, respectively, indicating an additive effect of the combined treatment. Compared to cagrilintide, IBI3040 displays a favorable PK profile, high solubility, and stability without fibril formation at physiological pH (7-8).

IBI3040 demonstrates superior receptor activation, robust weight loss effects compared to cargrilintide and eloralintide, and synergistic potential with semaglutide, supporting its development as a next-generation amylin analog for obesity treatment.

IBI3042 (weekly oral small-molecule GLP-1) Preclinical Results

ADA Reference: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity (Abstract No.: 2543-P)

IBI3042 is potentially the world's first once-weekly oral small-molecule GLP-1 receptor agonist candidate entering clinical studies by the end of 2026. The weekly dosing potential is offering a compelling new option for patients seeking a more convenient and manageable long-term treatment for type 2 diabetes and obesity.

IBI3042 exhibited GLP-1R activation in cAMP assays, but showed no β-arrestin recruitment in NanoBiT assays. In human GLP-1 receptor knock-in (GLP-1R KI) mice, IBI3042 (0.4 mg/kg P.O.) maintained significant glucose-lowering effects for at least 7 days, outperforming Orforglipron at the same dose.

In diet-induced obese (DIO) humanized GLP-1 receptor knock-in mice, IBI3042 at 1 mg/kg twice weekly showed comparable efficacy to Orforglipron 1.5 mg/kg once daily, while the 3 mg/kg twice-weekly dose demonstrated superior efficacy. In contrast, Orforglipron at 3 mg/kg twice weekly showed no notable efficacy.

In obese cynomolgus monkeys, IBI3042 produced robust, dose-dependent body weight reduction with twice-weekly oral dosing (1.5–4.5 mg/kg). The 1.5 mg/kg twice-weekly regimen achieved efficacy comparable to Orforglipron 1 mg/kg once daily, while the 4.5 mg/kg twice-weekly regimen demonstrated superior body weight reduction. Furthermore, the 7 mg/kg once-weekly regimen also matched the efficacy of Orforglipron 1 mg/kg once daily.

These compelling results position IBI3042 as a promising once-weekly oral treatment for obesity and type 2 diabetes, delivering a significantly more convenient and effective dosing option for patients.

IBI3046 (novel INHBE siRNA) Preclinical Results

ADA Reference: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study (Abstract No.: 2662-P)

IBI3046 is an INHBE-silencing RNAi therapeutic designed to enhance adipose lipolysis with sustained effects.

IBI3046 demonstrated potent and durable mRNA knockdown in hINHBE KI mouse model. In the efficacy study, IBI3046 resulted in a 13% reduction in body weight and a 50% decrease in fat mass relative to control. In combination therapy, IBI3046 administered with a low dose of GLP-1RA achieved 20% body weight loss and a 80% reduction in fat mass. Combining IBI3046 with GLP-1RAs may synergistically enhance fat loss while mitigating key limitations of current anti-obesity regimens. In addition, IBI3046 extended the duration of suppressed weight regain following drug withdraw.

IBI3046 enables Q3M-6M dosing, offering diabetes and obesity patients improved adherence and quality of life for glucose and weight control, thereby can potentially redefine the standard of metabolic disease management.

Dr. Lei Qian, Chief R&D Officer (General Biomedicine) of Innovent, stated, "At this year's ADA Scientific Sessions, we are pleased to present a series of new data in obesity and metabolic diseases, which is an important step in establishing Innovent as an emerging leader and innovator in this field. The multiple oral presentations of mazdutide, across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, further highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032 (oral daily GLP-1 small molecule), IBI3042 (oral weekly GLP-1 small molecule), IBI3040 (amylin) and IBI3046 (INHBE siRNA) represent key progresses of our next‑generation obesity pipeline with global potential, which are designed to address unmet needs around tolerability, muscle preservation, dosing convenience, durability of weight loss and management of obesity‑related comorbidities."

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 1 asset under NMPA review, 4 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Sciences Industry Awards. The company also was named the winner of the "Life Sciences Team of the Year" and won the "Outstanding Contribution Award." The Life Sciences Industry Awards are among Ireland's foremost industry recognition programs, celebrating excellence, innovation, and leadership across the country's pharmaceutical, biotechnology, medical device, and broader life sciences sectors.

The company was shortlisted across eight award categories, reflecting the breadth of capabilities and achievements demonstrated by its Ireland site. Among the honors received, WuXi Biologics' Manufacturing Science & Technology (MSAT) Team was named Life Sciences Team of the Year and subsequently selected for the Overall Excellence in Life Sciences award, recognizing the team's exceptional contributions to advancing manufacturing science, technology transfer, operational performance, and delivery excellence.

The recognition further reinforces WuXi Biologics Ireland's position as a strategic hub within the company's global network and highlights its continued commitment to quality, innovation, operational excellence, and sustainable growth. As demand for high-quality biologics manufacturing continues to grow, the Ireland site remains focused on delivering flexible and reliable solutions that support global clients across the development and commercialization lifecycle.

These latest honors build upon a series of major milestones achieved by the Ireland site in recent years, including HPRA GMP authorization and EMA approval for commercial manufacturing of innovative biologic products. Since commencing operations, the WuXi Biologics Ireland site has established itself as one of Europe's most advanced single-use biologics manufacturing facilities, earning international recognition for its operational excellence, innovation, and sustainability performance.  

Other accolades the Ireland site has received include the ISPE Facility of the Year Award and the Operational Excellence in Life Sciences Award. All together, these achievements underscore the site's growing role in supporting global biologics development and commercial manufacturing while contributing to the continued advancement of Ireland's thriving life sciences ecosystem.

WuXi Biologics' global manufacturing footprint spans China, the United States, Ireland, Germany, and Singapore, with 24 drug substance (DS) facilities and 18 drug product (DP) facilities currently in operation. This network provides integrated dual-sourcing solutions spanning DS and DP — from clinical development through commercial-scale manufacturing — at the highest levels of quality. As of 2025, WuXi Biologics had successfully passed 46 regulatory inspections worldwide, including 22 conducted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), achieving a 100% success rate with no critical findings and no data integrity issues.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)
*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts
Business
[email protected] 

Media
[email protected]

NVIDIA Corporation (NVDA.US) is collaborating with LG Group to develop humanoid robots and data centers, said CEO Jensen Huang.

Both parties are working together to research motor technologies and mechanical systems, aiming to integrate the future of humanoid robots with robotics technologies, he said. The two companies will also jointly build next-generation data centers.
~

AASTOCKS Financial News
Website: www.aastocks.com

US semiconductor stocks plunged last Friday (5th). This morning (8th), Samsung Electronics shares once sank below KRW300,000 and last dived more than 7% at KRW305,000, while SK Hynix shares dropped below KRW2 million and were last down 3.86%.

Jensen Huang, CEO of NVIDIA Corporation (NVDA.US), who is visiting Seoul, said that AI-related stocks are now very cheap and shareholders should be pleased as there could be even greater upside in the future.

Huang stated that demand for AI will continue to mushroom and that the future is very bright. It has become an established fact that AI will serve as core global infrastructure.

Earlier, NVIDIA reached a cooperation agreement of more than two years with SK Hynix, which can be extended. Under the agreement, NVIDIA chips will be produced at SK Hynix’s wafer fabrication plants and used by SK Telecom to support AI development.
~

AASTOCKS Financial News
Website: www.aastocks.com

NVIDIA Corporation (NVDA.US) and SK Hynix announced a multi-year technology partnership agreement, building on years of close joint R&D to advance next-generation memory technologies, accelerate the construction of global AI factories, and speed up semiconductor design and manufacturing.

The agreement provides supply support for advanced memory to address extended R&D cycles, advanced manufacturing processes and capital investments, thereby sustaining the build-out of global AI factories. SK Hynix will collaborate with NVIDIA to develop memory for the Vera Rubin AI supercomputer, Vera CPU, RTX Spark-powered personal computers, and the Jetson Thor robotics computing platform.

The two companies will apply AI technologies to semiconductor chip design and manufacturing, leveraging NVIDIA CUDA-X libraries and NVIDIA PhysicsNeMo to accelerate semiconductor simulation, TCAD processes and internal engineering codes.

SK Hynix will integrate NVIDIA Omniverse, OpenUSD scene optimization and NVIDIA cuOpt to advance digital twin technology for factories, enabling fully autonomous wafer fabrication plant operations.
~

AASTOCKS Financial News
Website: www.aastocks.com

NVIDIA Corporation (NVDA.US) Founder and CEO Jensen Huang will visit South Korea today (5th) and meet with the heads of several major South Korean enterprises, Yonhap News Agency reported, citing NVIDIA and industry sources. This marks his first trip to South Korea in seven months since his last visit in late October last year.

Huang is purportedly expected to enter the country via Gimpo Airport at around 1 p.m. local time and attend a dinner this evening with leaders of major South Korean conglomerates.

Attendees are set to include SK Group Chairman Chey Tae-won, Hyundai Motor Group Chairman Euisun Chung, LG Group Chairman Koo Kwang-mo, and NAVER Board Chairman Lee Hae-jin.
~

AASTOCKS Financial News
Website: www.aastocks.com

DENVER, June 4, 2026 /PRNewswire/ -- XPENG (NYSE: XPEV, HKEX: 9868), a leading China-based high-tech company, kicks off its key presence at CVPR 2026 (The IEEE/CVF Conference on Computer Vision and Pattern Recognition). Dr. Xianming Liu, Head of General Intelligence Center at XPENG, spoke at the inaugural Workshop on Deployment of Foundation Models for Embodied AI (WDFM-EAI), sharing insights with global counterparts including Tesla, NVIDIA and Waymo. This marks XPENG's third attendance at the prestigious conference.

From Technical Concept to Mass Production: VLA2.0 Achieves Key Technical Breakthrough

Dr. Xianming Liu systematically deconstructed the evolution of XPENG's physical AI technology system, from concept validation and technical refinement to full-scale mass production. First unveiled at CVPR 2025, XPENG's in-house foundation model has now achieved a critical leap: VLA2.0 has entered formal mass production, marking an industry-leading closed loop from pre-research to commercial deployment. Within its first month, VLA2.0 set an industry milestone with over 50% assisted driving mileage share, establishing a new benchmark in China's assisted driving sector.

First Technical Blueprint for World Model Unveiled, Advancing Physical-World Foundation Models

Dr. Xianming Liu introduced the world model as another core pillar of XPENG's foundation model system. XPENG is developing a world model capable of Deliberative Reasoning, Controllable Generation, and Long-Horizon Forecasting. Rather than competing, the world model and VLA2.0 complement each other: VLA2.0 learns "how to act" from human driving, while the world model learns "how the world changes after an action" by predicting future states and scene evolution. Together, they form XPENG's Physical-World Foundation Model, essentially pursuing the same goal: building a sufficiently powerful foundation model for the physical world.

XPENG specifies these three core capacities as essential for qualified world models and autonomous driving. Its R&D team has published three papers: X-World, X-Foresight, X-Cache, detailing corresponding R&D approaches.

Continuing Validation of Scaling Law: XPENG Accelerates Large-Scale Rollout of Physical AI

In the 12 months ending March this year, XPENG's cluster delivered a 1,010% uplift in per-GPU training efficiency and a 4,360% gain in single-job training efficiency, while GPU hardware utilization climbed from 40% to 90%, matching benchmarks set by top-tier global AI firms.

As VLA2.0's capabilities continue to expand, XPENG is accelerating the large-scale deployment of its core Physical AI applications: VLA2.0, Robotaxi, and Humanoid Robots. The IRON humanoid robot is progressing toward mass production by the end of 2026, with plans to enter XPENG's offline stores as a shopping guide in Q1 2027.

Appendix: XPENG World Model Related Academic Papers

X-World Paper: https://arxiv.org/pdf/2603.19979

X-World Official Site: https://x-world-1.github.io/

X-Cache Paper: https://arxiv.org/abs/2604.20289

X-Cache Official Site: https://x-cache-1.github.io/en/

X-Foresight Paper: https://arxiv.org/abs/2605.24892

X-Foresight Official Site: https://x-foresight-1.github.io/en/

About XPENG
Founded in 2014, XPENG is a leading Chinese AI-driven mobility company that designs, develops, manufactures, and markets Smart EVs, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to drive the Smart EV revolution through cutting-edge technology, shaping the future of mobility.

To enhance the customer experience, XPENG develops its full-stack advanced driver-assistance system (ADAS) technology and intelligent in-car operating system in-house, along with core vehicle systems such as the powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its Smart EVs are primarily manufactured at its facilities in Zhaoqing and Guangzhou, Guangdong province.

XPENG is listed on the New York Stock Exchange (NYSE: XPEV) and Hong Kong Exchange (HKEX: 9868).
For more information, please visit https://www.XPENG.com/.

Contacts:
For Media Enquiries:
XPENG PR Department
Email: [email protected]